ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1761

Fatigue in Patients with Systemic Lupus Erythematosus Is Independent of Their Disease Activity but Dependent on Their Damage Accrual and Body Mass Index

Adam Munday1, Zerai G. Manna1, Sarfaraz Hasni1, Randall Keyser2, Liana Wooten2 and Ann Biehl3, 1National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health, Bethesda, MD, 2George Mason University Department of Rehabilitation Science, Fairfax, VA, 3Department of Pharmacy, National Institutes of Health Clinical Center, Bethesda, MD

Meeting: 2016 ACR/ARHP Annual Meeting

Date of first publication: September 28, 2016

Keywords: fatigue and systemic lupus erythematosus (SLE)

  • Tweet
  • Email
  • Print
Session Information

Date: Monday, November 14, 2016

Title: Systemic Lupus Erythematosus – Clinical Aspects and Treatment - Poster II: Damage Accrual and Quality of Life

Session Type: ACR Poster Session B

Session Time: 9:00AM-11:00AM

Background/Purpose: Fatigue is omnipresent in patients with SLE. According to one study 80-90 % of the subjects report some degree of fatigue. This has huge impact on the patient’s activities of daily living and overall quality of life. The fatigue associated with SLE was traditionally considered to be a consequence of SLE disease activity and difficult to measure and quantify in clinical practice. Recent recommendations from several international rheumatology societies and patient advocacy groups have focused on improving quality of life by focusing on issues such as fatigue during clinical encounters with SLE patients. The goal of this study is to measure severity of fatigue in our SLE cohort and to identify any predictors of fatigue.

Methods: We administered a well validated tool of fatigue measure Fatigue Severity Scale (FSS) to consecutive, consenting SLE subjects during their routine outpatient visits at a tertiary care center. Their demographic data, lab values, comorbidities and current medications were recorded at the time of visit. A rheumatologist blinded to the patient FSS scores calculated the SELENA-SLEDAI and SLICC/ACR damage index scores. Statistical analysis using SAS Software (SAS Institute Inc. Cary, NC) was done to identify any predictive variables using multiple regression models and a stepwise multiple regression models.

Results: FSS was collected from 100 unique patients over a period of 9 months (Table 1). The majority of patients reported significant fatigue with minimal or no disease activity. FSS scores were unrelated to SLEDAI, disease duration, and plasma hemoglobin concentration (Table 2). FSS correlated significantly with SLICC/ACR (p=0.0123) and BMI (p=0.0337). Ethnicity, type of medications, comorbidities, and especially fibromyalgia, were found not to be predictive of fatigue in this cohort.

Conclusion: Results of this study suggest that organ damage accrual may be associated with the severity of fatigue in patients with SLE, independently of their disease activity or duration. Overall the results may implicate, in addition to aggressive early treatment to minimize damage accrual, lifestyle modification such as diet and increased physical activity to lower BMI as a potential therapeutic adjunct to improve fatigue in SLE.  

Table-1-Details of patients enrolled in Fatigue Severity scale

Variables

N=100

Age (Years)
n

100

Mean ±SD

45.5±13.1

Range

17–78

Disease Duration (years)
n

100

Mean ±SD

15.4±11.2

Range

1–50

Race/Ethnicity, N (%)
African American

26 (26.0 %)

Asian

19 (19.0 %)

Caucasian

25 (25.0%)

Hispanic

30 (30.0 %)

Gender, N (%)
Female

93 (93.0%)

Male

7 (7.0 %)

FSS
n

100

Mean ±SD

4.0 ±1.7

Range

1–7

SLEDAI Score
n

100

Mean ±SD

3.3±2.8

Range

0–12

SLICC/ACR
n

100

Mean ±SD

1.7±1.8

Range

0–8

BMI
n

99

Mean ±SD

27.4±6.1

Range

16.8–48.9

                                               

Table-2. Multiple Regression model Results predicting fatigue adjusted for key confounders.

Variable

β, beta estimate

Std. Error

95% confidence Interval

P-Value(*)

Lower

Upper

SLEDAI

0.058

0.062

-0.065

0.181

0.3493

SLICC/ACR

0.271

0.106

0.060

0.481

0.0123

Disease Duration

-0.014

0.017

-0.048

0.019

0.3914

BMI

0.060

0.028

0.005

0.115

0.0337

Hemoglobin

0.165

0.124

-0.082

0.412

0.1875

P Value (*) were obtained using Multiple Regression model

 


Disclosure: A. Munday, None; Z. G. Manna, None; S. Hasni, None; R. Keyser, None; L. Wooten, None; A. Biehl, None.

To cite this abstract in AMA style:

Munday A, Manna ZG, Hasni S, Keyser R, Wooten L, Biehl A. Fatigue in Patients with Systemic Lupus Erythematosus Is Independent of Their Disease Activity but Dependent on Their Damage Accrual and Body Mass Index [abstract]. Arthritis Rheumatol. 2016; 68 (suppl 10). https://acrabstracts.org/abstract/fatigue-in-patients-with-systemic-lupus-erythematosus-is-independent-of-their-disease-activity-but-dependent-on-their-damage-accrual-and-body-mass-index/. Accessed .
  • Tweet
  • Email
  • Print

« Back to 2016 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/fatigue-in-patients-with-systemic-lupus-erythematosus-is-independent-of-their-disease-activity-but-dependent-on-their-damage-accrual-and-body-mass-index/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology